Larson Financial Group LLC Buys New Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Larson Financial Group LLC bought a new stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 8,162 shares of the company’s stock, valued at approximately $116,000.

Several other institutional investors also recently bought and sold shares of the stock. Sage Rhino Capital LLC grew its stake in shares of Takeda Pharmaceutical by 7.6% in the 3rd quarter. Sage Rhino Capital LLC now owns 11,751 shares of the company’s stock worth $182,000 after buying an additional 831 shares in the last quarter. Legacy Wealth Asset Management LLC grew its stake in shares of Takeda Pharmaceutical by 0.7% in the 3rd quarter. Legacy Wealth Asset Management LLC now owns 124,967 shares of the company’s stock worth $1,933,000 after buying an additional 851 shares in the last quarter. Vestmark Advisory Solutions Inc. grew its stake in shares of Takeda Pharmaceutical by 1.4% in the 3rd quarter. Vestmark Advisory Solutions Inc. now owns 63,630 shares of the company’s stock worth $984,000 after buying an additional 870 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its stake in shares of Takeda Pharmaceutical by 5.7% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 16,433 shares of the company’s stock worth $254,000 after buying an additional 883 shares in the last quarter. Finally, Simplicity Solutions LLC grew its stake in shares of Takeda Pharmaceutical by 0.4% in the 3rd quarter. Simplicity Solutions LLC now owns 213,515 shares of the company’s stock worth $3,303,000 after buying an additional 955 shares in the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Price Performance

Takeda Pharmaceutical stock opened at $13.07 on Friday. The firm has a 50-day moving average price of $14.09 and a 200-day moving average price of $14.21. The firm has a market capitalization of $41.35 billion, a PE ratio of 19.80, a price-to-earnings-growth ratio of 3.02 and a beta of 0.53. The company has a current ratio of 1.06, a quick ratio of 0.55 and a debt-to-equity ratio of 0.64. Takeda Pharmaceutical Company Limited has a 12-month low of $13.05 and a 12-month high of $17.11.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Thursday, February 1st. The company reported $0.51 earnings per share (EPS) for the quarter. The firm had revenue of $7.52 billion during the quarter. Takeda Pharmaceutical had a net margin of 6.90% and a return on equity of 12.57%. As a group, equities research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.5 EPS for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.